Biotech · Public company · Gaithersburg, MD, US
Novavax Inc
Ticker NVAX · SEC CIK 0001000694
Track this companyFree. Adds Novavax Inc to your Dealase workspace and tells you when its record changes.
Clinical trials220 recruiting or active
Pipeline programs36From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline36
- Fluzone QuadrivalentPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Formulation bufferPhase 3 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- NanoFluPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- NVX-Cov2373Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NVX-CoV2373 (5μg)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NVX-CoV2601 (35μg)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NVX-CoV2601 (5μg)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccinePhase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NVX-CoV2601(50μg)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NVX-CoV2705 VaccinePhase 3 · Severe Acute Respiratory Syndrome Coronavirus 2 InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Prototype/XBB.1.5 Bivalent Vaccine (5 µg)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- RSV F vaccine with adjuvantPhase 3 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- RSV-F VaccinePhase 3 · Respiratory Syncytial Virus (RSV)ClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS antigen/Matrix-M AdjuvantPhase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)Phase 3 · SARS-CoV InfectionClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)Phase 3 · SARS-CoV InfectionClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)Phase 3 · SARS-CoV InfectionClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)Phase 3 · SARS-CoV InfectionClinicalTrials.gov · fetched Nov 12, 2026
- XBB.1.5 Vaccine (Booster)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- XBB.1.5 Vaccine (single dose)Phase 3 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Flublok QuadrivalentPhase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Fluzone HDPhase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Fluzone HD - Day 0Phase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Fluzone HD - Day 21Phase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Influenza VaccinePhase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Matrix-M AdjuvantPhase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- NanoFluPhase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- NanoFlu (Quad-NIV)Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- RSV F vaccine (0.5mL injection)Phase 2 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS - Phase 1Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- NVX-CoV2705COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Pfizer mRNA COVID-19 vaccineCOVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- protein subunit: Novavax COVID-19 vaccineCOVID-19ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials22
- Efficacy and Safety of NVX-CoV2705PHASE4 · TERMINATED · started Nov 20, 2025ClinicalTrials.gov NCT07086222 · fetched Nov 12, 2026
- Safety and Immunogenicity of NVX-CoV2705PHASE3 · COMPLETED · started Oct 9, 2025ClinicalTrials.gov NCT07079670 · fetched Nov 12, 2026
- A Strain Change Study for SARS-CoV-2 rS VaccinesPHASE3 · COMPLETED · started Oct 14, 2024ClinicalTrials.gov NCT06409663 · fetched Nov 12, 2026
- Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United StatesPHASE4 · COMPLETED · started Sep 19, 2024ClinicalTrials.gov NCT06633835 · fetched Nov 12, 2026
- The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 InfectionPHASE4 · COMPLETED · started Nov 22, 2023ClinicalTrials.gov NCT06065176 · fetched Nov 12, 2026
- Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed PopulationsPHASE2 · COMPLETED · started Nov 20, 2023ClinicalTrials.gov NCT06027229 · fetched Nov 12, 2026
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesPHASE2_PHASE3 · COMPLETED · started Oct 16, 2023ClinicalTrials.gov NCT05925127 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.PHASE2_PHASE3 · COMPLETED · started Sep 7, 2023ClinicalTrials.gov NCT05975060 · fetched Nov 12, 2026
- Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesPHASE3 · COMPLETED · started Aug 16, 2023ClinicalTrials.gov NCT05973006 · fetched Nov 12, 2026
- Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesPHASE3 · COMPLETED · started Mar 28, 2023ClinicalTrials.gov NCT05875701 · fetched Nov 12, 2026
- Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsPHASE2_PHASE3 · COMPLETED · started Jul 22, 2022ClinicalTrials.gov NCT05468736 · fetched Nov 12, 2026
- Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsPHASE3 · COMPLETED · started Jul 11, 2022ClinicalTrials.gov NCT05463068 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2PHASE3 · COMPLETED · started Dec 27, 2020ClinicalTrials.gov NCT04611802 · fetched Nov 12, 2026
- Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M AdjuvantPHASE1_PHASE2 · COMPLETED · started May 25, 2020ClinicalTrials.gov NCT04368988 · fetched Nov 12, 2026
- Phase 3 Pivotal Trial of NanoFlu™ in Older AdultsPHASE3 · COMPLETED · started Oct 14, 2019ClinicalTrials.gov NCT04120194 · fetched Nov 12, 2026
- Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older AdultsPHASE2 · TERMINATED · started Sep 24, 2018ClinicalTrials.gov NCT03658629 · fetched Nov 12, 2026
- Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)PHASE1_PHASE2 · COMPLETED · started Sep 18, 2017ClinicalTrials.gov NCT03293498 · fetched Nov 12, 2026
- A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationPHASE3 · COMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02624947 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy of an RSV F Vaccine in Older AdultsPHASE3 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02608502 · fetched Nov 12, 2026
- Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.PHASE2 · COMPLETED · started Oct 1, 2015ClinicalTrials.gov NCT02593071 · fetched Nov 12, 2026
- Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly AdultsPHASE2 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02266628 · fetched Nov 12, 2026
- RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.PHASE2 · COMPLETED · started Sep 1, 2014ClinicalTrials.gov NCT02247726 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026